Accropeutics’ drug has hit the goals of a phase 2 psoriasis trial in China, prompting the biotech to pledge to “accelerate” the TYK2/JAK1 inhibitor’s clinical development.

Accropeutics Inc. has announced the dosing of the first patient in its Phase Ib clinical trial for AC-101, aimed at treating moderate to severe Ulcerative Colitis.

Accropeutics Inc. has successfully closed a $12 million Series B Plus financing round to enhance their clinical trials, focusing on immune-mediated diseases.

Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). Cash runway…

Accropeutics has announced promising Phase 2 trial results for AC-201, an oral TYK2/JAK1 inhibitor, aimed at treating plaque psoriasis, paving the way for further development.

Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics, Cadrenal and Inovio: Altimmune to test its incretin in addiction: Following the path set by Novo Nordisk last week, Altimmune said Thursday at its R ...

Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation Efficacy and safety findings from this Phase 2 trial support advancing AC-201 into Phase 3 development for …